Market closed · data as of 27 Aug 2026 · source NSE via Alphave. Open the live chart →
Sun Pharmaceutical Industries is India's largest pharmaceutical company, spanning branded generics in India (the largest domestic formulations franchise), US generics (including subsidiary Taro), emerging markets, and APIs. Its key differentiator is a global specialty portfolio — dermatology and ophthalmology brands such as Ilumya, Winlevi, Cequa and Odomzo — which drives an increasing share of revenue and R&D spend. Growth drivers are the specialty ramp-up, Indian chronic-therapy leadership and select complex generics.
It is India's largest pharma company by revenue and market cap and the leader in the domestic prescription market.
Sun Pharmaceutical Industries Ltd. is a constituent of NIFTY 100, NIFTY 200, NIFTY 50, NIFTY 500, NIFTY HEALTHCARE, NIFTY PHARMA, BSE SENSEX. See where it sits on the market heatmap →
Consolidated annual figures taken from Sun Pharmaceutical Industries Ltd.'s own filed statements — not estimates, and not restated by us. The most recent period shown is FY26 (year ended 31 Mar 2026).
Per-share figures are not restated. Shares outstanding changed from 239.93 crore to 0.00 crore in FY25, consistent with a bonus issue or stock split. Each year's EPS and book value below are as that year was filed, on that year's share count — so the per-share line falls across FY25 even where profit did not. Compare the absolute figures (EBITDA, free cash flow, total debt) and the margins across that boundary, not the per-share ones.
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| EPS (basic, ₹) | 47.80 | 45.60 | 39.90 |
| Book value / share (₹) | 349.60 | 21,74,55,100.77 | 279.69 |
| Return on equity | 13.7% | 15.1% | 14.3% |
| Return on capital employed | 17.2% | 17.2% | 15.3% |
| Operating margin | 25.3% | 24.1% | 21.6% |
| Net margin | 19.7% | 20.9% | 19.8% |
| EBITDA | ₹17,731 Cr | ₹15,272 Cr | ₹13,023 Cr |
| Free cash flow | ₹8,810 Cr | ₹11,944 Cr | ₹9,933 Cr |
| Total debt | ₹4,082 Cr | ₹1,870 Cr | ₹2,846 Cr |
| Debt to equity | 0.05 | 0.03 | 0.04 |
| Interest coverage | 43.6 | 54.9 | 43.9 |
| Current ratio | 2.82 | 2.89 | 2.56 |
| Shares outstanding | 2,39,93,00,000 | 3,333 | 2,39,93,00,000 |
Open the full income statement, balance sheet and cash flow for SUNPHARMA →
As disclosed for the quarter ended 30 Jun 2026.
Institutional ownership changes quarter to quarter. See daily FII and DII flows across the market →
Companies Alphave classifies in the same sub-sector, closest by market capitalisation.